Attached files

file filename
EX-32 - EXHIBIT 32 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh32.htm
EX-10.8 - EXHIBIT 10.8 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_8.htm
EX-10.6 - EXHIBIT 10.6 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_6.htm
EX-10.7 - EXHIBIT 10.7 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_7.htm
EX-31.1 - EXHIBIT 31.1 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh31_1.htm
EX-10.3 - EXHIBIT 10.3 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_3.htm
EX-10.4 - EXHIBIT 10.4 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_4.htm
EX-31.2 - EXHIBIT 31.2 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh31_2.htm
EX-10.1 - EXHIBIT 10.1 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_1.htm
EX-10.5 - EXHIBIT 10.5 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_5.htm
EXCEL - IDEA: XBRL DOCUMENT - GENEREX BIOTECHNOLOGY CORPFinancial_Report.xls
10-Q - FORM 10-Q - GENEREX BIOTECHNOLOGY CORPgnbt112013form10q.htm
EX-10.9 - EXHIBIT 10.9 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_9.htm
EX-10.2 - EXHIBIT 10.2 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_2.htm
EX-10.12 - EXHIBIT 10.12 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_12.htm
EX-10.11 - EXHIBIT 10.11 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_11.htm
EX-10.13 - EXHIBIT 10.13 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_13.htm
EX-10.10 - EXHIBIT 10.10 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_10.htm

Exhibit 10.14

 

 

OPTION AGREEMENT

 

This Option Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the "Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to Eric von Hofe (the "Optionee") pursuant to the Generex Biotechnology Corporation Amended 2001 Stock Option Plan (the “Plan”), a copy of which is attached to this Option Agreement and incorporated into this Option Agreement by reference. The Option is subject to the terms, conditions, limitations and restrictions set forth in the Plan, including the following:

 

a. The date of grant of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the Option is 400,000.

 

b. The purchase price (the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c. The Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan: 400,000 shares will vest on January 1, 2014. Only options that have vested may be exercised.

 

d. Unless sooner terminated pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e. The Optionee shall pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise, as provided in the Plan.

 

f. The rights and interests of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event of the death of the Optionee, by will or by the laws of descent and distribution.

 

g. Any notice to the Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s principal offices.

 

IN WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee effective as of the date of grant of the Option.

 

 

GENEREX BIOTECHNOLOGY CORPORATION   ACCEPTED AND AGREED:
       
       
Per: /s/ Mark Fletcher   /s/ Eric von Hofe
Name: Mark A. Fletcher,   Eric von Hofe, Optionee
  President & CEO    
       
Per: /s/ Stephen Fellows    
Name: Stephen Fellows,    
  Chief Financial Officer